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INTRODUCTION
Toxoplasmosis, caused by an intracellular protozoan parasite, Toxoplasma gondii, is
widespread throughout the world. The disease is of major medical and veterinary importance,
being a cause of congenital disease and abortion in humans and in domestic animals.[1] In
addition, it has gained importance recently due to toxoplasma encephalitis in AIDS patients.[2]
T. gondii was discovered 100 years ago. Its identification was rapidly followed by the
recognition that it was a human pathogen. During the past 100 years, the spectrum of
diseases caused by this ubiquitous pathogen has expanded to include both congenital and
acute infections as well as the recognition of diseases caused by this pathogen in the
immune-compromised host. Recent data on behavioural changes in animals due to chronic
toxoplasmosis is leading to research on the effect of this pathogen on the behaviour of
humans.[3] Experimental studies on T. gondii have resulted in it becoming a model organism
for studies on host pathogen interactions. Integration of clinical and experimental data on
T. gondii should continue to lead to important insights into improvements in diagnosis for
clinical management and vaccine development for control of toxoplasmosis.
THE PARASITE
Toxoplasma gondii is a ubiquitous protozoan parasite that is estimated to infect one-third
of the world’s human population. It can infect many species of warm-blooded animals and
is a significant zoonotic and veterinary pathogen. It has been 100 years since T. gondii was
initially described in the tissues of Ctenodactylus gundi, a North African rodent, by Nicolle
and Manceaux .[4] Splendore, in Brazil, reported on the identification of this organism in the
tissues of a rabbit.[5]
The genus was named by Nicolle and Manceaux as Toxoplasma for its bow-like shape
(from Greek: toxo = bow or arc; plasma = creature). Other forms of Toxoplasma including
tissue cysts were recognised to exist by several researchers, but it was not until the 1960s
and 1970s that the parasite was identified as a coccidian.[6] The cat was identified as the
definitive host by several groups working independently, including Frenkel et al.[7]  Further
details of the history of the discovery of the pathogen are described in recent reviews.[8, 9]
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T. gondii infects a wide range of intermediate hosts that include different species of
mammals. Acute toxoplasmosis in these hosts is characterised by intracellular growth of the
rapidly dividing tachyzoite stage in many tissues. As the immune response controls the
acute infection, some of the tachyzoites become encysted, particularly in the muscles and
brain, in a dormant stage termed the bradyzoite. These cysts contain hundreds of bradyzoites
which are retained for years. If the tissue that contains these cysts is eaten by a non-feline
carnivore, the bradyzoites are released in the intestine and again yield infection, characterised
initially by rapid growth of tachyzoites and ultimately by the persistence of encysted
bradyzoites. However, when encysted bradyzoites are eaten by a member of the cat family,
the sexual cycle occurs in the intestine, resulting in the production of oocysts. When a
sporulated oocyst (ovoid and measuring approximately 10 × 12 µm) is ingested by a mammal,
the sporozoites are released and infect the intestinal epithelial cells. They become rapidly
multiplying tachyzoites that first produce an acute and then a chronic infection with encysted
bradyzoites, thereby completing the natural life cycle (Figure 1).
Tachyzoites are crescent shaped and about 6 µm long and 2 µm wide. They are coated
with three unit membranes, which form the pellicle. The anterior end of the tachyzoite is
marked by the presence of a conoid, a hollow, truncated cone of spirally wound fibres that
are likely to be microtubules. The rhoptries are club shaped, densely osmophilic structures
whose narrow ends terminate in the conoid. Micronemes are situated close to the rhoptries
and are believed to have a secretory function. Dense organs are distributed throughout the
Figure 1. Life cycle of Toxoplasma gondii
Source: Modified from: http://www.omafra.gov.on.ca/english/livestock/swine/facts/04-055.htm
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cytoplasma of tachyzoites. Proteins from the dense granules are released into the external
environment as excreted/secreted antigens. Bradyzoites differ from tachyzoites in their
higher content of micronemes, amylopectin granules and stage-specific antigens.[10]
Sexual forms of the parasite are found in the intestinal epithelium of definitive hosts
such as domestic cats which then transform into oocysts which are subsequently shed in
the environment. Oocysts, remarkably stable environmentally, are transmitted to other hosts
through inadvertent ingestion. Humans acquire T. gondii through ingestion of undercooked
meat, contact with feline faeces and rarely through drinking contaminated water or through
transplantation of a contaminated organ.[11]
For clinical purposes, toxoplasmosis can be divided for convenience into five infection
categories: (i) those acquired by immuno-competent patients; (ii) those acquired during
pregnancy; (iii) those acquired congenitally; (iv) those acquired by or reactivated in immuno-
deficient patients; and (v) ocular infections. In any category, clinical presentations are not
specific for toxoplasmosis, and a wide differential diagnosis must be considered. Furthermore,
methods of diagnosis and their interpretations may differ for each clinical category.[1,12,13,14]
 RECOMBINANT T.GONDII SURFACE 1 (SAG1; P 30)
The immuno-dominant surface antigen of T. gondii, surface antigen 1 (SAG1; previously
named P30), is commonly expressed in  Escherichia coli as a fusion protein containing the
mature part of the SAG1 protein supplied with six histidyl residues in the N-terminal end.
The construction can be produced in large amounts, is easy to purify, and is recognised by
anti-SAG1 monoclonal antibodies, Toxoplasma-specific acute phase immunoglobulin M
(IgM) antibodies and chronic-phase IgG human antibodies. Native mature SAG1 protein is
presumed to be post-translationally modified by removal of the signal sequence and the C
terminus, the latter upon addition of the GPI anchor.[15,16] Santoro et al. demonstrated that
SAG1 antigen express on the surface of intra- and extra-cellular tachyzoites.[17]
Rodriguez et al. suggested that SAG1 is the most immunogenic constituent of
tachyzoites, and that a single region of this molecule contains most of the immunogenic
activity.[18] Some epidemiological studies were carried out by researchers using this antigen
and in some experimental studies, this antigen was used for vaccination.  Others used this
antigen for diagnosis of congenital toxoplasmosis. In conclusion, the 30 kDa protein gene
of Toxoplasma tachyzoites surface antigen (SAG1) that was cloned in expression vector
and the expressed protein (30 kDa) has been widely used for diagnosis of toxoplasmosis
using the ELISA system.
Although serological tests give satisfactory results, production of reliable and standard
reagents continues to be a major constraint in serodiagnosis leading to inter-assay variability.
Most conventional test kits employ T. gondii tachyzoites grown in mice or in tissue culture
which are often contaminated with extra parasite material. Therefore, use of purified
recombinant proteins in suitably designed serotests is the only alternative for specific and
sensitive results. For diagnostic applications, SAG1 is a commonly used antigen because it
is the most immuno-dominant and stage-specific, present in tachyzoite stage and not in
bradyzoite stage.[19]
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We have generated this  immuno-dominant surface antigen of Toxoplasma gondii,
surface antigen 1 (SAG1), which was expressed in Escherichia coli as a fusion protein
containing a majority of the SAG1 protein supplied with six histidyl residues in the N-
terminal end. The recombinant protein was purified on a Ni-chelate column and then on a
fast performance liquid chromatography column and was in a non-reduced condition. It
was recognised by T. gondii specific human immuno-globulin G (IgG) and IgM antibodies
as well as by a mouse monoclonal antibody (S13) recognising only non-reduced native
SAG1. Antibodies induced in mice by the recombinant SAG1 recognised native SAG1 from
the T. gondii RH isolate in culture. This recombinant SAG1 is suitable for use in detecting
human anti-SAG1-specific IgG and IgM antibodies from sera of patients (Figure. 2). Assays
based on the recombinant SAG1 are expected to be easier to standardise and to be more
reproducible because only a single protein with a few immuno-dominant epitopes is used.
The immuno-dominant surface antigen of Toxoplasma gondii, surface antigen 1 (SAG1;
previously named P30), was expressed in Escherichia coli as a fusion protein containing
the mature part of the SAG1 protein supplied with six histidyl residues in the N-terminal end.
The construction can be produced in large amounts, is easy to purify, and is recognised by
anti-SAG1 monoclonal antibodies, Toxoplasma-specific acute phase immunoglobulin M
(IgM) antibodies and chronic-phase IgG human antibodies. Native mature SAG1 protein is
presumed to be post-translationally modified by removal of the signal sequence and the C
terminus, the latter upon addition of the GPI anchor.[20]
Most workers therefore cloned only the sequence coding for the mature part of the
protein, residues 49 through 323 (2), into an E. coli expression vector, pGH433 (12), using
Figure 2. Reactivity of the immunodominant surface antigen of Toxoplasma gondii, surface
antigen 1 (SAG1) mol. Wt 30 kDa with  A. T. gondii specific human immunoglobulin G (IgG) and
B. IgM antibodies from sera of patients.  Recombinant SAG1 is suitable for use in diagnostic
systems for detecting anti-SAG1-specific IgG and IgM antibodies.
Source: Data came from work funded by a grant from the Ministry of Science, Technology and
Innovarion Science Fund 02-01-04-SF0801
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PCR. An oligo-nucleotide encoding six histidyl residues and a factor Xa cleavage site (13)
was cloned into the vector in frame with the SAG1-coding region (pDH26), giving rise to a
recombinant SAG1 (rSAG1).
The B- and T-cell epitopes of the SAG1 protein have been studied by several groups
and it has been found that SAG1 contains one immuno-dominant region in the middle of the
protein, with repetitive epitopes containing all of the B-cell epitopes.[21,22]  The B-cell epitopes
are conformational since human T. gondii-immune sera do not recognise the reduced SAG1.
The SAG1 gene codes for 12 cysteine residues, and the immuno-genicity of the recombinant
protein depends entirely on the correct folding. In E. coli, the formation of disulfide bonds
takes place within the periplasm, while we presume that our rSAG1 is situated in the cytoplasm,
since it does not contain any secretion signal sequence.
Studies on immunisation of mice with a fusion protein consisting of glutathione S-
transferase and SAG1 produced in E. coli have shown decreased T. gondii infection of
macrophages, but the immunogenicity of rSAG1 was not reported. The fusion products
showed the same immunological phenotypes, since rabbits immunised with either of the
two fusion proteins elicited significant antibody responses against rSAG1, but only rabbits
immunised with rSAG1 expressed in eukaryotic cells displayed serological reactivity against
a tachyzoite lysate.[23]
The B- and T-cell epitopes of the SAG1 protein have been studied and it has been
found that SAG1 contains one immuno-dominant region  in the middle of the protein, with
repetitive epitopes containing all of the B-cell epitopes.[24]  The B-cell epitopes are
conformational since human T. gondii-immune sera do not recognise the reduced SAG1
The SAG1 gene codes for 12 cysteine residues, and the immuno-genicity of the recombinant
protein depends entirely on the correct folding. In E. coli, the formation of disulfide bonds
takes place within the periplasm, but some presume that rSAG1 is situated in the cytoplasm,
since it does not contain any secretion signal sequence. The shift in mass between the
reduced rSAG1 (33 kDa) and the non-reduced rSAG1 (31 kDa) and the disappearance of all
reactivity of rSAG1 under reducing conditions indicate that at least the disulfide bridges
necessary for the immune reactivity with human sera and the S13 monoclonal antibody are
normally formed in rSAG1. Even though the native SAG1 protein is phosphorylated, most
rSAG1 fusion protein is not since phosphorylation modifications do not take place in E.
coli, and phosphorylation is therefore not important for the immuno-genicity of the B-cell
epitopes.[23, 24]
SERODIAGNOSIS OF TOXOPLASMOSIS
Diagnosis of T. gondii infection or toxoplasmosis in humans is made by biological,
serological, histological, or molecular methods or by some combination of these methods.
Clinical signs of toxoplasmosis are non-specific and are not sufficiently characteristic for a
definite diagnosis. In fact, toxoplasmosis mimics several other infectious diseases. Detection
of T. gondii antibodies (mainly immunoglobulin G [IgG] and IgM) in patients may aid
diagnosis. IgG antibodies usually appear within 1 to 2 weeks of acquisition of the infection,
peak within 1 to 2 months, decline at various rates, and usually persist for life.[25,26]
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IgM antibodies may appear earlier and decline more rapidly than IgG antibodies, so the
detection of IgG antibodies may be helpful for diagnosis of chronically infected patients, if
IgM antibodies are negative. An IgM test is still used by most laboratories to determine if
a patient has been infected recently or in the distant past; because of the hurdles posed in
interpreting a positive IgM test result, confirmatory testing should always be performed.
[27,28]
There are numerous serological procedures available for the detection of humoral
antibodies; these include the Sabin-Feldman dye test, the indirect hemagglutination assay,
the indirect fluorescent antibody assay, the direct agglutination test, the latex agglutination
test, the enzyme-linked immunosorbent assay (ELISA), and the immunosorbent
agglutination assay test.[29]
Most of these immuno-diagnostic tests are not easy to apply in the field, for example,
the ELISA or the indirect fluorescence antibody assay, since these techniques require
special equipment and reagents. Performing any of these tests even in the laboratory
generally takes time, sometimes with overnight incubation steps; otherwise, enzyme reagents
would need a cold chain for delivery. In such situations, a rapid, simple, and inexpensive
colorimetric assay with robust reagents and no instrumentation could have many diagnostic
applications.
The choice of the appropriate diagnostic method(s) and its (their) interpretation may
differ for each clinical category. The dot immuno-binding assay, using an nitrocellulose
(NC) membrane as a test matrix, is becoming widely used in simple qualitative research
applications.[30]  Colloidal gold-labeled antibodies are also used in dot blot assays to avoid
use of the sometimes problematic enzyme-labeled detecting antibodies. Recently, some
colloidal dye particles were screened to label antigen or antibody for the detection of
antibody or antigen; compared with gold or enzyme; the colloidal dye is cheaper or easier to
preserve.[31]  The colloidal dye particle technique utilises the concepts of ELISA, dot blot
assays, colloidal dye-labeled antigen or antibody, and immuno-chromatography to produce
an inexpensive, robust, NC based dipstick test for antibody or antigen detection. Since it
requires no instrumentation for qualitative detection of antigen or antibody, it has many
potential field applications.
Previously, our laboratory used monoclonal antibodies (MAbXC3) conjugated with a
colloidal dye to detect Brugia malayi excretory antigens on a NC membrane dipstick based
on immuno-chromatography (DIA). The DIA for detecting antigens in patients with brugian
filariasis showed very high sensitivity, specificity, and positive predictive value. The assay
is useful for detection of active cases of lymphatic filariasis  in areas where the disease is
endemic and is rapid, simple, cheap and effective.[32]
Since the diagnosis of clinical toxoplasmosis is often difficult, serologic procedures
have been employed to aid in diagnosis. These include the Sabin-Feldman dye test, the
indirect hemagglutination (IHA) test, the indirect immuno-fluorescence (IFA) test  and the
enzyme-linked immunosorbent assay (ELISA).[33] The two most used assays, the IFA test
and ELISA, require expensive fluorescence microscopes or photometers. Recently, we
successfully applied an ELISA using microlitre volumes of a monoclonal antibody (DiMAb)
onto nitrocellulose paper (Dot-ELISA) to detect antigenemia in canine dirofilariasis.[34] This
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dot-ELISA for canine dirofilariasis is highly versatile and a rapid microprocedure and  is  as
sensitive and specific as ELISA. It does not require a photometer, and is field-portable. In
addition, the Dot-ELISA can be easily standardised with respect to incubation times and
temperatures, antigen and reagent stabilities, enzyme-conjugated antibody specificity, and
reproducibility. [35]
However, serodiagnosis may also become complicated by inapparent past infection
with Toxoplasrna. In the United States, serological incidence of toxoplasmosis increases to
between 30% and 50% in the over-20 age group; incidence varies with geographic area and
with age.[36]  Thus, isolated positive serum IgG titres may only indicate past exposure to T.
gondii, complicating the interpretation of sero-diagnostic findings. Postitive IgM titres are
more indicative of acute infection with T. gondii. In terms of detecting Toxoplasma-specific
antibodies in the population, the Dot-ELISA, ELISA, and IFA tests are equivalent. The
three assays varied by <5% in detection of IgG and <3% in detecting IgM antibodies The
significantly higher geometric mean titres observed in the Dot-ELISA are comparable to
those of the ELISA and IFA tests but do not necessarily result in greater assay sensitivity.
This phenomenon has been observed in the Dot-ELISA for sero-diagnosis of human visceral
leishmaniasis and indicates that this assay regularly shows higher titres than other serologic
tests. Nevertheless all of the assays detected significant levels of IgM antibodies.
Although serological tests give satisfactory results, production of reliable and standard
reagents continues to be a major constraint in sero-diagnosis leading to inter-assay variability.
Most conventional test kits employ T. gondii tachyzoites grown in mice or in tissue culture
which are often contaminated with extra parasite material. Therefore, use of purified
recombinant proteins in suitably designed sero-tests is the only alternative for specific and
sensitive results. For diagnostic applications, several target genes of T. gondii have been
cloned and expressed. Among the T. gondii antigens, surface antigen 1 (SAG1) is the
choice because it is the most immuno-dominant and stage-specific, present in tachyzoite
stage and not in bradyzoite stage, while granule protein 7 (GRA7) produces very strong
antibody response in the acute phase of infection.[37] Despite potential advantages of these
recombinant antigens in sero-diagnosis, only limited studies have considered more than
one antigen in enzyme-linked immunosorbent assays (ELISAs). The current paradigm in
sero-diagnosis is the use of two recombinant proteins, SAG1, a tachyzoite stage-specific
protein and GRA7 separately and/or as a cocktail of these proteins in ELISA format to
replace the whole tachyzoite proteins as antigens for specific detection of T. gondii infection.
 VACCINATION PROSPECTS AGAINST TOXOPLASMOSIS
Treatment of this disease is difficult due to toxic effects of available drugs, and reinfection
occurs rapidly. Under the present scenario, development of either new antitoxoplasma
drugs or a vaccine is an attractive alternative.
In the last few years, there has been considerable progress towards the development
of a vaccine for toxoplasmosis, and a vaccine based on the live attenuated S48 strain was
developed for veterinary uses.[38] However, this vaccine is expensive, causes side effects
and has a short shelf life. Furthermore, this vaccine may revert to a pathogenic strain and
therefore  is not suitable for human use. Various experimental studies have shown that it
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may be possible to develop a vaccine against human toxoplasmosis. This section of this
review highlights the protective immune response generated by T. gondii as well as the
current status of development of a vaccine for toxoplasmosis.
In recent years, significant progress has also been made in the identification of vaccine
candidates which can induce a protective immune response (Table 1). Most of the work has
focused on surface antigens of tachyzoites. SAG1 (30 kDa), SAG2 (22 kDa), SAG3 (43 kDa),
which are are major surface antigens of tachyzoites.[39] Amongst them, SAG1 is the
predominant vaccine candidate. Excretory secretory antigens of T. gondii also play an
important role in the stimulation of the protective immune system.[40, 41]  These antigens are
expressed by both tachyzoites and encysted bradyzoites. The major components of excretory
secretory antigens are GRA molecules. [42]  GRA1 (23 kDa), GRA4 (40 kDa) and GRA7 (29
kDa) have also been identified as vaccine candidates. Recently, ROP2 (56 kDa) antigen
(expressed by tachyzoites, bradyzoites and sporozoites) has also been proposed as a vaccine
candidate against toxoplasmosis.[43]
Humans are generally infected by ingesting oocysts released in cat faeces or consuming
meat from infected animals containing the long-lived tissue cysts. After ingesting infective
tissue cysts or oocysts, tachyzoites are released which first invade and multiply in intestinal
epithelial cells.. From the gastro-intestinal tract, tachyzoites are disseminated to other organs
of the human body. In the lumen of the gut, intra-epithelial lymphocytes are located among
the epithelial cells.[44, 45]  They participate in modulating host immunity through the release
of various cytokines, most apparently interferon-c (IFN-c) and induce immunity.[9] Similarly
to intra-epithelial lymphocytes, mesenteric lymph node lymphocytes may migrate to the gut
and prevent parasite invasion.[46]
T. gondii induces a potent cell-mediated immune response.Tachyzoites stimulate
macrophages to produce interleukin-12 (IL-12) and tumour necrosis factor-a (TNF-a). [47, 48]
IL-12, in turn, activates natural killer cells and T cells to produce IFN-c, which  is crucial for
resistance.[11] IFN-c and TNF-a act synergistically to mediate killing of tachyzoites by
macrophages.[11] The combination of these two cytokines results in the enhanced production
of free radicals and nitric oxide (NO), which also can affect parasite killing.[49, 50] NO is
produced as a result of activation of inducible nitric oxide synthase (iNOS). iNOS is induced
in T. gondii replication in murine cells but not in human macrophages. In an in vivo study
with iNOS-deficient mice, the protective role of NO against T. gondii infection was tissue
specific rather than systemic.[51] Other in vitro studies demonstrated that IFN-c-induced
antitoxoplasma activity in human cell depends on the induction of indoleamine 2,3
dioxygenase (IDO), which is the rate-limiting enzyme for the L-tryptophan-L kynurenine
pathway. In the absence of tryptophan, parasitic growth becomes restricted. Thus, IDO and
iNOS are involved in the immuno-modulatory role of IFN-c. Recent studies suggest that
there is an anti-toxoplasma mechanism of cross-regulation between iNOS and IDO and that
the expression of the main antiparasitic effector mechanism for iNOS or IDO may vary
among mouse tissues. Among the T cell population, CD8+ T cells are considered to be the
major effector cells responsible for protection against T. gondii, with CD4+ T cells playing
a synergistic role. Furthermore, the depletion of the total T cell population abrogates
protective immunity against toxoplasma challenge in the immunised animals. [52] CD8+ T
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cells from TS-4 vaccinated animals are able to proliferate and secrete IFN-c in response to
recall antigen for a longer duration than the CD4+ T cells from the same mice. Immune CD8+
T cells from both infected mice and humans secrete IFN-c and exhibit in vitro cytotoxicity
towards infected cells. The CD4+ Th1 cells exert their protective effect through the
production of IFN-c and IL-2. Conversely, the cytokines produced by CD4+ Th2 cells, such
as IL-4, IL-5 and IL-10, are associated with down-regulation of protective cell-mediated
immune responses. These T cell subsets are able to cross-regulate their activity. The host
immune response blocks the multiplication of tachyzoites, resulting in the formation of
cysts containing bradyzoites in all the tissues. A variety of stress conditions include pH
shock, heat shock, mitochondrial inhibitors, chemical stress and NO induced bradyzoite
formation.[53]
Control of multiplication of tachyzoites is largely dependent on endogenous INF-c,
with partial involvement of TNFRp55 and iNOS. In contrast, induction of bradyzoite-specific
antigen expression and cyst formation during toxoplamosis seem to be dependent on INF-
c, but independent of TNFRp55 and iNOS functions. The development of large numbers of
cysts are controlled by major histo-compatibility complex class I gene, Ld, in mice However,
toxoplasma strain-specific differences have been observed. Recurrence of T. gondii infection
and consequent disease is common in congenitally infected individuals. Immuno-suppressive
therapy favours disease reactivation. Murine studies have found that neutralisation of
IFN-c or TNF-a or inhibition of NO production leads to relapse of chronic infection, resulting
in active disease with numerous tachyzoites.[54] Detailed studies are therefore required for
the determination of the mechanism of conversion from bradyzoite to tachyzoite.
T. gondii mutant strains, viz., S48, TS-4 and T-203, have been identified as vaccine
candidates.[55] The live tachyzoites of strain S48 have been used as the commercial vaccine for
ovine toxoplasmosis. Following subcutaneous inoculation of naive sheep (sero-negative for
T. gondii) with the commercial vaccine, the parasite multiplies in the local draining lymph
node, causing a mild fibrile response. Peak titres of antibody are reached by 6 weeks. The
immunity induced by this vaccine is likely to involve both CD4+ and CD8+ T cells and IFN-c.
However, such a vaccine is not suitable for human use due to reactivation to the pathogenic
form.
The natural site of infection for T. gondii is the mucosal surface of the intestine.
Protective immunity obtained after natural infection with T. gondii points to the importance
of developing a vaccine that stimulates mucosal defence. When lysate of tachyzoites with
cholera toxin (mucosal adjuvant) was administered orally, significant protection was noted
in mice. The intranasal route of administration of vaccine is more effective than intragastric
immunisation, as it generates an earlier, strong mucosal response. When SAG1 plus cholera
toxin was administered intranasally, it provided significant protection and reduced the cyst
burden. However, cholera toxin cannot be included in vaccine formulation for use in humans
due to its toxicity. LTR72 and LTK63 are the two non-toxic mutants of heatliable enterotoxin
which have been used with bacterial antigens and showed protection against different
infections after intragastric or nasal vaccination. Mice immunised with SAG1 plus these
mucosal adjuvants had significantly fewer cysts. These combinations induced strong
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systemic and mucosal humoral response. Salbutumol, currently used as an anti-asthmatic
drug, was also tested for its potential adjuvant activity for nasal vaccination.
Mice vaccinated with SAG1 with salbutamol showed significant decrease in cerebral
cysts. [56]. Nasal delivery of the antigen SAG1 plus LTR72 as the adjuvant produced a
cellular response in local (mesenteric lymph node) and systemic sites. This cellular response
was important for protection against infection with T. gondii. Now these non-toxic mutants
are the most attractive candidates for the development of mucosally delivered vaccine. One
of the goals of a vaccination protocol is to be able to appropriately direct the T helper
response. In naturally occurring T. gondii infection, the Th1 immune response is predominant.
Therefore, a vaccination protocol that directs immune response to the Th1 type is desirable.
Significant protection was found with SAG1 with liposome. Liposomes are known to be
a particularly effective stimulator of CD8+ T lymphocytes. Vaccination with r-SAG1 produced
by Escherichia coli, Pichia pastoris or an insect cell culture system demonstrated significant
protection in experimental animals. [57]
We have successfully immunised mice against lethal challenge using  E. coli-expressed
r-SAG plus alum induces protective immunity in mice. Immunised mice survive longer than
the non-imunised  (Figure 3). However, further studies require an adjuvant enhancing specific
CTL response, which is believed to be the main mechanism behind protective immunity to
T. gondii. Immunisation with r-SAG1 plus r IL-12 directed humoral and cellular immunity
towards a Th1 pattern and reduced the brain parasite load in mice. Immunisation with r-
Figure 3. Survival analysis after lethal challenge with T. gondii tachyzoites in mice vaccinated
with vaccine rSAG1-alum, T. gondii tachzoite lysate and alum only as control.
Source: Data from work funded byResearch University Grant Scheme RUGS 04-01-07-030.
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SAG1 plus SBAs1 (Th1 response inducer adjuvant) induced significant protection against
materno-foetal transmission in guinea pig. [58]  DNA vaccine has been shown to be a powerful
method for the induction of specific humoral and cellular immune responses. It is a novel
method involving the injection of the naked DNA plasmid into the host, whose cells express
the encoded protein. Mice immunised with plasmid encoding the SAG1 gene (Pit SAG1)
showed 80–100% protection. It influenced the immune response towards a Th1 type.
Furthermore, DNA vaccine encoding SAG1 increased the survival time of animals and
reduced the number of brain cysts in rodents.[55] However, there was a slight increase in
survival days of infected mice immunised with pGRA4  or plasmid encoding GRA1, GRA7
and ROP2 or BCG strain secreted GRA1.[59]  Recently, genetically modified skins have been
developed, and these grafts produced some therapeutic proteins. The SAG1 gene-vaccinated
mouse skin graft was effective for protection against challenge infection.[60] However, the
molecular basis of the gene vaccine effect against T. gondii infection remains to be determined.
In conclusion, these vaccine candidates (alone or in cocktail) demonstrated the
development of significant protection in animal models. The route of administration of
vaccine candidates and use of suitable adjuvants have been shown to be important in
eliciting an immune response. Recent progress in characterising potentially protective
defence mechanisms during naturally acquired and experimental toxoplasmosis will help to
define the immune response which should be elicited by vaccination. Future vaccine design
has to account for the stage-specific regulation of immunity against T. gondii to prevent
abortion and damage as well as to reduce cyst formation in the intermediate host.
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